TC BioPharm LtdNASDAQ:TCBPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE5.3050
- TODAY'S CHANGE (%)0.3350 (6.7404%)
- Bid / Lots5.2800/ 9
- Ask / Lots5.3300/ 6
- Open / Previous Close5.0000 / 4.9700
- Day Range
- 52 Week Range
- Volume336,443
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TCBP |
|---|---|---|
| 09:32 ET | 1433 | 5.01 |
| 09:33 ET | 2629 | 5.0199 |
| 09:35 ET | 3500 | 4.965 |
| 09:37 ET | 3722 | 4.95 |
| 09:39 ET | 2962 | 4.92 |
| 09:42 ET | 1976 | 4.9956 |
| 09:46 ET | 100 | 4.9896 |
| 09:48 ET | 600 | 4.9787 |
| 09:50 ET | 270 | 4.97 |
| 09:51 ET | 1343 | 4.945 |
| 09:53 ET | 400 | 4.9617 |
| 09:57 ET | 2200 | 4.92 |
| 10:02 ET | 500 | 4.95 |
| 10:04 ET | 380 | 4.9522 |
| 10:06 ET | 550 | 4.9802 |
| 10:08 ET | 1025 | 4.95 |
| 10:09 ET | 1200 | 4.9501 |
| 10:11 ET | 937 | 4.93 |
| 10:13 ET | 1800 | 4.936 |
| 10:15 ET | 500 | 4.9699 |
| 10:18 ET | 100 | 4.9375 |
| 10:20 ET | 500 | 4.9331 |
| 10:24 ET | 474 | 4.93 |
| 10:26 ET | 100 | 4.97 |
| 10:27 ET | 300 | 4.93 |
| 10:29 ET | 1094 | 4.94 |
| 10:33 ET | 150 | 4.9436 |
| 10:36 ET | 540 | 4.97 |
| 10:38 ET | 4065 | 4.92 |
| 10:40 ET | 700 | 4.965 |
| 10:42 ET | 270 | 4.9899 |
| 10:44 ET | 600 | 4.99 |
| 10:45 ET | 1064 | 4.94 |
| 10:47 ET | 115 | 4.92 |
| 10:49 ET | 2296 | 4.9 |
| 10:51 ET | 1294 | 4.8801 |
| 10:58 ET | 1600 | 4.92 |
| 11:00 ET | 1900 | 4.9518 |
| 11:02 ET | 700 | 4.9599 |
| 11:03 ET | 3998 | 4.9729 |
| 11:05 ET | 200 | 4.9387 |
| 11:12 ET | 1000 | 4.9076 |
| 11:14 ET | 972 | 4.95 |
| 11:16 ET | 1430 | 4.95 |
| 11:18 ET | 500 | 4.92 |
| 11:20 ET | 500 | 4.93 |
| 11:21 ET | 500 | 5.01 |
| 11:23 ET | 600 | 4.95 |
| 11:25 ET | 200 | 4.9737 |
| 11:30 ET | 1821 | 4.9794 |
| 11:32 ET | 1999 | 5 |
| 11:34 ET | 3000 | 5.033 |
| 11:36 ET | 900 | 5.0291 |
| 11:38 ET | 400 | 5.005 |
| 11:39 ET | 200 | 5.0279 |
| 11:43 ET | 1000 | 4.9901 |
| 11:45 ET | 250 | 4.9661 |
| 11:48 ET | 319 | 4.9481 |
| 11:56 ET | 2069 | 4.9926 |
| 11:57 ET | 18359 | 4.9401 |
| 11:59 ET | 7682 | 5.1116 |
| 12:01 ET | 4222 | 5.0845 |
| 12:03 ET | 4768 | 5.19 |
| 12:06 ET | 22659 | 5.1599 |
| 12:08 ET | 11284 | 5.13 |
| 12:10 ET | 79655 | 5.45 |
| 12:12 ET | 20518 | 5.53 |
| 12:14 ET | 14597 | 5.392 |
| 12:15 ET | 7065 | 5.33 |
| 12:17 ET | 11081 | 5.34 |
| 12:19 ET | 7279 | 5.3 |
| 12:21 ET | 10879 | 5.31 |
| 12:24 ET | 5580 | 5.3247 |
Jan 30, 2023
BRIEF-TC Biopharm Announces Hiring Of Chief Clinical Officer Bree Harlin To Lead Global Clinical Division, from 9:34AM ET on Monday Jan 30, 2023 by Thomson Reuters
9:34AM ET on Monday Jan 30, 2023 by Thomson ReutersTC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division, from 8:30AM ET on Monday Jan 30, 2023 by PR Newswire
8:30AM ET on Monday Jan 30, 2023 by PR Newswire
Jan 26, 2023
--HC Wainwright Starts TC Biopharm (Holdings) at Buy With $9 Price Target, from 8:31AM ET on Thursday Jan 26, 2023 by MT Newswires
8:31AM ET on Thursday Jan 26, 2023 by MT Newswires
Jan 19, 2023
BRIEF-TC Biopharm Receives Notice Of Non-Compliance With Nasdaq's Listing Rule 5550(B)(1), from 8:42AM ET on Thursday Jan 19, 2023 by Thomson Reuters
8:42AM ET on Thursday Jan 19, 2023 by Thomson Reuters
Jan 18, 2023
Top Premarket Gainers, from 7:45AM ET on Wednesday Jan 18, 2023 by MT Newswires
7:45AM ET on Wednesday Jan 18, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TC BioPharm Ltd | 4.0M | -0.2x | --- |
Acura Pharmaceuticals Inc | 3.3M | -1.8x | --- |
Ensysce Biosciences Inc | 2.5M | 0.0x | --- |
Helix BioMedix Inc | 5.2M | -1.5x | --- |
OpGen Inc | 4.9M | -2.0x | --- |
Salarius Pharmaceuticals Inc | 5.8M | -0.2x | --- |
Company Information
TC BioPharm Limited is a clinical-stage biopharmaceutical company. The Company is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma-delta T cell therapies for the treatment of infectious disease. The Company's platform technology allows Company to design specific therapies to treat a range of cancers and infectious diseases with off-the-shelf allogeneic gamma-delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma-delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma-delta T cell product, being used for the treatment of COVID-19. The Company also provides in-house and partner programs at the pre-clinical stage focused on developing CAR-modified allogeneic gamma delta T-cell products targeting solid and hematological indications.
Contact Information
- Headquarters
- Maxim 1, 2 Parklands WayHONITON, United Kingdom ML1 4WR
- Phone
- 141-433-7557
- Fax
- ---
Executives
- Chief Executive Officer
- Michael Leek
- Chief Financial Officer
- Martin Thorp
- Chief Operating Officer
- Angela Scott
- Company Secretary
- Toby Rintoul
- Director
- Bryan Kobel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.0M |
|---|---|
Revenue (TTM) | $2.4M |
Shares Outstanding | 795.0K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-22.97 |
Book Value | $-0.73 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -631.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
